JP2019510006A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510006A5 JP2019510006A5 JP2018544466A JP2018544466A JP2019510006A5 JP 2019510006 A5 JP2019510006 A5 JP 2019510006A5 JP 2018544466 A JP2018544466 A JP 2018544466A JP 2018544466 A JP2018544466 A JP 2018544466A JP 2019510006 A5 JP2019510006 A5 JP 2019510006A5
- Authority
- JP
- Japan
- Prior art keywords
- hal
- disease
- replaced
- compound
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000004432 carbon atom Chemical group C* 0.000 claims 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 206010012289 Dementia Diseases 0.000 claims 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- -1 NR 8 Inorganic materials 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims 3
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims 3
- 208000027089 Parkinsonian disease Diseases 0.000 claims 3
- 206010034010 Parkinsonism Diseases 0.000 claims 3
- 208000034799 Tauopathies Diseases 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 2
- 206010018341 Gliosis Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 208000017004 dementia pugilistica Diseases 0.000 claims 2
- 230000007387 gliosis Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 208000023697 ABri amyloidosis Diseases 0.000 claims 1
- 208000017227 ADan amyloidosis Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 208000009093 Diffuse Neurofibrillary Tangles with Calcification Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 201000004066 Ganglioglioma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims 1
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000018642 Semantic dementia Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 201000006061 fatal familial insomnia Diseases 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 206010023497 kuru Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000001282 primary progressive aphasia Diseases 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 claims 1
- 0 CC1(*)OC(*=IC=C2)=C2O1 Chemical compound CC1(*)OC(*=IC=C2)=C2O1 0.000 description 8
- CBXMULHQEVXJDI-UHFFFAOYSA-N C1COc(cccc2)c2OC1 Chemical compound C1COc(cccc2)c2OC1 CBXMULHQEVXJDI-UHFFFAOYSA-N 0.000 description 1
- HBEDSQVIWPRPAY-UHFFFAOYSA-N C1c(cccc2)c2OC1 Chemical compound C1c(cccc2)c2OC1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N c1cnc2[n]1cccc2 Chemical compound c1cnc2[n]1cccc2 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621006636 | 2016-02-25 | ||
| IN201621006636 | 2016-02-25 | ||
| PCT/EP2017/054268 WO2017144633A1 (en) | 2016-02-25 | 2017-02-24 | Glycosidase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019510006A JP2019510006A (ja) | 2019-04-11 |
| JP2019510006A5 true JP2019510006A5 (OSRAM) | 2020-03-26 |
Family
ID=58159073
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544466A Withdrawn JP2019510006A (ja) | 2016-02-25 | 2017-02-24 | グリコシダーゼ阻害剤 |
| JP2019545961A Active JP7082446B2 (ja) | 2016-02-25 | 2017-08-24 | スルホキシイミングリコシダーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545961A Active JP7082446B2 (ja) | 2016-02-25 | 2017-08-24 | スルホキシイミングリコシダーゼ阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11612599B2 (OSRAM) |
| EP (1) | EP3419971B1 (OSRAM) |
| JP (2) | JP2019510006A (OSRAM) |
| KR (1) | KR20180132629A (OSRAM) |
| CN (2) | CN108884077A (OSRAM) |
| AU (1) | AU2017222958B2 (OSRAM) |
| CA (1) | CA3012560A1 (OSRAM) |
| EA (1) | EA201991697A1 (OSRAM) |
| MA (1) | MA43677A (OSRAM) |
| MX (1) | MX2018010192A (OSRAM) |
| WO (1) | WO2017144633A1 (OSRAM) |
| ZA (1) | ZA201905405B (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40532A (fr) | 2014-08-28 | 2021-04-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| US10556902B2 (en) * | 2016-02-25 | 2020-02-11 | Asceneuron Sa | Glycosidase inhibitors |
| WO2018153508A2 (en) * | 2017-02-24 | 2018-08-30 | Asceneuron S.A. | Sulfoximine glycosidase inhibitors |
| MX381953B (es) | 2016-02-25 | 2025-03-13 | Asceneuron S A | Sales de derivados de piperazina obtenidas por adicion de acidos. |
| CN110300752A (zh) | 2016-12-16 | 2019-10-01 | 詹森药业有限公司 | 单环oga抑制剂化合物 |
| EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
| EP3755352A4 (en) * | 2018-02-20 | 2021-12-22 | Edgewise Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MOTION DISORDERS |
| WO2019243531A1 (en) * | 2018-06-20 | 2019-12-26 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| JP2021527663A (ja) * | 2018-06-20 | 2021-10-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｏｇａ阻害化合物 |
| JP2021527687A (ja) * | 2018-06-21 | 2021-10-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｏｇａ阻害剤化合物 |
| AU2019291101A1 (en) * | 2018-06-21 | 2021-01-07 | Janssen Pharmaceutica Nv | OGA inhibitor compounds |
| TWI726329B (zh) | 2018-06-22 | 2021-05-01 | 美商美國禮來大藥廠 | 2,3-二氫呋喃并[2,3-b]吡啶化合物 |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| WO2020039028A1 (en) * | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| CN113166083A (zh) * | 2018-08-22 | 2021-07-23 | 阿森纽荣股份公司 | 用作糖苷酶抑制剂的哌嗪衍生物的琥珀酸盐和富马酸盐酸加成盐 |
| TWI716107B (zh) * | 2018-09-26 | 2021-01-11 | 美商美國禮來大藥廠 | 6-氟-2-甲基苯并[d]噻唑-5-基化合物 |
| CN111039946A (zh) * | 2018-10-15 | 2020-04-21 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
| WO2020163689A1 (en) * | 2019-02-08 | 2020-08-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | 20-hete formation inhibitors |
| WO2021094312A1 (en) | 2019-11-11 | 2021-05-20 | Janssen Pharmaceutica Nv | Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds |
| WO2021110656A1 (en) | 2019-12-02 | 2021-06-10 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| CN114929337A (zh) * | 2019-12-18 | 2022-08-19 | 詹森药业有限公司 | Oga抑制剂化合物 |
| IL293931A (en) | 2019-12-18 | 2022-08-01 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| WO2021123291A1 (en) | 2019-12-18 | 2021-06-24 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| US20230271965A1 (en) * | 2020-06-03 | 2023-08-31 | Kineta, Inc. | Bicyclic heteroarenes and methods of their use |
| CN112028839B (zh) * | 2020-09-30 | 2022-04-12 | 中国海洋大学 | 一种医药中间体环烷烃并嘧啶二酮化合物的合成方法 |
| CN117396490A (zh) * | 2021-05-14 | 2024-01-12 | Bm医药咨询有限公司 | 用于预防和治疗病毒感染的双环杂环化合物 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1311316A (fr) | 1961-04-12 | 1962-12-07 | Science Union Et Compagnie Soc | Nouveaux dérivés de la pipérazine et leurs préparations |
| NL127996C (OSRAM) | 1963-11-19 | |||
| US3485757A (en) | 1964-11-23 | 1969-12-23 | Atomic Energy Commission | Thermoelectric composition comprising doped bismuth telluride,silicon and boron |
| DE1595923A1 (de) * | 1965-02-20 | 1969-11-27 | Merck Ag E | 1-Aralkyl-4-(thiazolyl-2)-piperazine und Verfahren zu ihrer Herstellung |
| GB1165283A (en) | 1967-01-17 | 1969-09-24 | Science Union & Cie | New Purine Derivatives and processes for prepararing them |
| US4600025A (en) | 1982-11-18 | 1986-07-15 | Grigg Ronald E | Smoking products comprising nicotine substitutes |
| JPH07505648A (ja) | 1992-04-15 | 1995-06-22 | メルク シヤープ エンド ドーム リミテツド | アザサイクリック化合物 |
| IL118768A (en) | 1995-07-12 | 2000-10-31 | Akzo Nobel Nv | Diphenylmethane piperidine derivatives pharmaceutical compositions containing them and a method for their preparation |
| TW504510B (en) | 1996-05-10 | 2002-10-01 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives |
| AU6852898A (en) | 1997-04-17 | 1998-11-11 | Takeda Chemical Industries Ltd. | Thermogenic composition and benzazepine thermogenics |
| WO1999021850A1 (en) | 1997-10-24 | 1999-05-06 | Neurogen Corporation | 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl)piperazines being dopamine d4 receptor subtype ligands |
| EP1389189A2 (en) | 2001-05-22 | 2004-02-18 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
| US6982259B2 (en) | 2002-04-30 | 2006-01-03 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
| MXPA04012440A (es) | 2002-06-12 | 2005-04-28 | Abbott Lab | Antagonistas de receptor de hormona concentradora de melanina. |
| EP1531815B1 (en) | 2002-06-27 | 2014-09-24 | Novo Nordisk A/S | Glucokinase activators |
| DE60330456D1 (de) | 2002-07-05 | 2010-01-21 | Targacept Inc | N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung |
| MXPA05002622A (es) | 2002-09-09 | 2005-09-08 | Johnson & Johnson | Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano. |
| CA2518839A1 (en) | 2003-04-18 | 2004-11-04 | Eli Lilly And Company | (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists |
| CA2526374A1 (en) | 2003-05-21 | 2004-12-02 | Banyu Pharmaceutical Co., Ltd. | 2-aminoquinoline derivatives |
| DK1723128T3 (da) | 2004-01-06 | 2013-02-18 | Novo Nordisk As | Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer |
| US7253168B2 (en) | 2004-04-07 | 2007-08-07 | Neurogen Corporation | Substituted 1-benzyl-4-substituted piperazine analogues |
| HU227119B1 (en) | 2004-07-29 | 2010-07-28 | Richter Gedeon Nyrt | Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| HUP0401522A2 (en) | 2004-07-29 | 2006-04-28 | Richter Gedeon Vegyeszet | New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation |
| CA2819464A1 (en) | 2005-03-01 | 2006-09-08 | Matthew Macauley | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| EP1705177A1 (en) | 2005-03-23 | 2006-09-27 | Schering Aktiengesellschaft | N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents |
| TW200724140A (en) | 2005-05-27 | 2007-07-01 | Eisai Co Ltd | Hydantoin compounds |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| WO2007006760A1 (en) | 2005-07-08 | 2007-01-18 | Novo Nordisk A/S | Dicycloalkyl urea glucokinase activators |
| US20090192169A1 (en) | 2006-03-31 | 2009-07-30 | Ian Egle | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators |
| EP2029593A1 (en) | 2006-05-22 | 2009-03-04 | AstraZeneca AB | Indole derivatives |
| US20080051387A1 (en) | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
| WO2008012623A1 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| EP2057171A4 (en) | 2006-08-31 | 2010-04-21 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE INHIBITORS AND APPLICATIONS THEREOF |
| US20100022517A1 (en) | 2006-12-18 | 2010-01-28 | Richards Lori A | Ophthalmic formulation of rho kinase inhibitor compound |
| US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2009011904A1 (en) | 2007-07-19 | 2009-01-22 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
| PL2215075T3 (pl) | 2007-10-26 | 2014-04-30 | Janssen Pharmaceutica Nv | Pochodne chinolinonu jako inhibitory PARP |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| EP2276736A1 (en) | 2008-04-17 | 2011-01-26 | Pfizer Inc. | 4- [3- (aryloxy) benzyliden]-3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors |
| CA2719784A1 (en) | 2008-04-17 | 2009-10-22 | Pfizer Inc. | Ether benzylidene piperidine 5-membered aryl carboxamide compounds |
| US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
| JP2010065024A (ja) | 2008-08-14 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤 |
| WO2010021381A1 (ja) | 2008-08-22 | 2010-02-25 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
| WO2010022517A1 (en) | 2008-08-29 | 2010-03-04 | Saint Mary's University | Use of gluconacetobacter with reduced use of nitrogen fertilizer to improve beet crop production |
| EP2336104A4 (en) | 2008-09-02 | 2012-01-25 | Nissan Chemical Ind Ltd | ORTHOSUBSTITUTED HALOALKYL SULFONANILIDE DERIVATIVE AND HERBICIDE |
| TW201030007A (en) | 2009-02-06 | 2010-08-16 | Gruenenthal Gmbh | Substituted spiro-amides as b1r modulators |
| EA201171098A1 (ru) | 2009-03-02 | 2012-04-30 | Сертрис Фармасьютикалз, Инк. | 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина |
| US20100240720A1 (en) | 2009-03-20 | 2010-09-23 | Burnham Institute For Medical Research | Allosteric jnk inhibitors |
| WO2010108268A1 (en) | 2009-03-23 | 2010-09-30 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JP2010270034A (ja) | 2009-05-20 | 2010-12-02 | Sumitomo Chemical Co Ltd | アミド化合物並びにその植物病害防除用途 |
| EP2445340B1 (en) | 2009-06-22 | 2016-05-18 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| DE102009049679A1 (de) | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
| US9120781B2 (en) | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| JP2013537233A (ja) | 2010-09-17 | 2013-09-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 脂肪酸合成酵素阻害剤 |
| EP2638052B1 (en) | 2010-11-08 | 2017-03-22 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
| WO2012061972A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| CA2822493C (en) | 2010-12-23 | 2018-11-20 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| GB201103526D0 (en) | 2011-03-02 | 2011-04-13 | Summit Corp Plc | Selective glycosidase inhibitors and uses thereof |
| WO2012124744A1 (ja) | 2011-03-14 | 2012-09-20 | 大正製薬株式会社 | 含窒素縮合複素環化合物 |
| HUE029390T2 (en) | 2011-08-25 | 2017-02-28 | Merck Patent Gmbh | Pirano [3,2-d] [1,3] thiazole derivatives as glucosidase inhibitors |
| EP2773207B1 (en) | 2011-10-31 | 2018-03-07 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| AR092031A1 (es) | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | Inhibidores del canal de potasio medular externo renal |
| EP2882733B1 (en) | 2012-08-08 | 2017-04-26 | Novartis Tiergesundheit AG | Substituted azines as pesticides |
| US9522883B2 (en) | 2012-08-31 | 2016-12-20 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| ES2723883T3 (es) | 2013-03-14 | 2019-09-03 | Merck Patent Gmbh | Inhibidores de glicosidasa |
| CN103435606A (zh) | 2013-08-22 | 2013-12-11 | 中国药科大学 | CDK2与GSK3β双重抑制剂及用途 |
| ME02883B (me) | 2013-12-05 | 2018-04-20 | Pfizer | PIROLO[2,3-d]PIRIMIDINIL-, PIROLO[2,3-b]PIRAZINIL- I PIROLO[2,3-d] PIRIDINILAKRILAMIDI |
| EP2913330A1 (en) | 2014-02-27 | 2015-09-02 | Laboratoire Biodim | Condensed derivatives of imidazole useful as pharmaceuticals |
| RU2659070C9 (ru) | 2014-04-23 | 2018-08-24 | Дарт Нейросайенс (Кайман) Лтд. | ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 |
| AR101197A1 (es) | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Pirimidinas 2,5-sustituidas |
| MA40532A (fr) * | 2014-08-28 | 2021-04-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
| HUE050664T2 (hu) | 2014-10-08 | 2020-12-28 | UCB Biopharma SRL | Tetrahidroizokinolin-származékok |
| EP3204374B1 (en) | 2014-10-08 | 2019-04-03 | UCB Biopharma SPRL | Isoindoline derivatives |
| NZ730728A (en) | 2014-11-20 | 2022-04-29 | Merck Patent Gmbh | Heteroaryl compounds as irak inhibitors and uses thereof |
| TWI770525B (zh) | 2014-12-30 | 2022-07-11 | 美商瓦洛健康公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| AU2016287478B2 (en) | 2015-07-02 | 2021-10-21 | Janssen Sciences Ireland Uc | Antibacterial compounds |
| SG11201803605YA (en) | 2015-11-02 | 2018-05-30 | Janssen Pharmaceutica Nv | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND |
| US10065963B2 (en) | 2015-11-06 | 2018-09-04 | Incyte Corporation | Heterocyclic compounds as PI3K-γ inhibitors |
| WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US10323038B2 (en) | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2017091818A1 (en) | 2015-11-25 | 2017-06-01 | Lieber Institute For Brain Development | Comt inhibiting methods and compositions |
| DK3389658T3 (da) | 2015-12-18 | 2021-01-11 | Merck Sharp & Dohme | Glycosidasehæmmere og anvendelser deraf |
| US10556902B2 (en) | 2016-02-25 | 2020-02-11 | Asceneuron Sa | Glycosidase inhibitors |
| MX381953B (es) | 2016-02-25 | 2025-03-13 | Asceneuron S A | Sales de derivados de piperazina obtenidas por adicion de acidos. |
| WO2018153508A2 (en) | 2017-02-24 | 2018-08-30 | Asceneuron S.A. | Sulfoximine glycosidase inhibitors |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| EP3419974B1 (en) | 2016-02-25 | 2021-05-05 | Asceneuron SA | Process for the separation of enantiomers of piperazine derivatives |
| JP6994767B2 (ja) | 2016-06-21 | 2022-01-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| WO2018026371A1 (en) | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Dual nav1.2/5ht2a inhibitors for treating cns disorders |
| JP2020503300A (ja) | 2016-12-16 | 2020-01-30 | ヤンセン ファーマシューティカ エヌ．ベー． | 二環式ｏｇａ阻害剤化合物 |
| CN110300752A (zh) | 2016-12-16 | 2019-10-01 | 詹森药业有限公司 | 单环oga抑制剂化合物 |
| TWI654978B (zh) | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| CN110267961A (zh) | 2017-02-06 | 2019-09-20 | 詹森药业有限公司 | Oga抑制剂化合物 |
| CA3045745A1 (en) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazin as oga inhibitors |
| AR111693A1 (es) | 2017-05-25 | 2019-08-07 | Lilly Co Eli | Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga |
| EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| CN113166083A (zh) | 2018-08-22 | 2021-07-23 | 阿森纽荣股份公司 | 用作糖苷酶抑制剂的哌嗪衍生物的琥珀酸盐和富马酸盐酸加成盐 |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| US20220143042A1 (en) | 2019-02-22 | 2022-05-12 | Asceneuron Sa | Fused glycosidase inhibitors |
-
2017
- 2017-02-24 US US16/078,159 patent/US11612599B2/en active Active
- 2017-02-24 AU AU2017222958A patent/AU2017222958B2/en not_active Revoked
- 2017-02-24 CN CN201780011547.3A patent/CN108884077A/zh active Pending
- 2017-02-24 KR KR1020187025792A patent/KR20180132629A/ko not_active Withdrawn
- 2017-02-24 MX MX2018010192A patent/MX2018010192A/es unknown
- 2017-02-24 JP JP2018544466A patent/JP2019510006A/ja not_active Withdrawn
- 2017-02-24 EP EP17707008.3A patent/EP3419971B1/en active Active
- 2017-02-24 WO PCT/EP2017/054268 patent/WO2017144633A1/en not_active Ceased
- 2017-02-24 CA CA3012560A patent/CA3012560A1/en not_active Withdrawn
- 2017-02-24 MA MA043677A patent/MA43677A/fr unknown
- 2017-08-24 JP JP2019545961A patent/JP7082446B2/ja active Active
- 2017-08-24 CN CN201780089984.7A patent/CN110770226B/zh active Active
- 2017-08-24 EA EA201991697A patent/EA201991697A1/ru unknown
-
2019
- 2019-08-15 ZA ZA2019/05405A patent/ZA201905405B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510006A5 (OSRAM) | ||
| JP2019506430A5 (OSRAM) | ||
| JP2014527060A5 (OSRAM) | ||
| JP2014503527A5 (OSRAM) | ||
| NZ788543A (en) | Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy | |
| CN115768750B (zh) | Gcn2调节剂化合物 | |
| AU2016373533B2 (en) | Novel compounds | |
| JP7341034B2 (ja) | プロテオパチーの処置のためのベンジリデングアニジン誘導体の新規な治療的使用 | |
| JP2018536641A5 (OSRAM) | ||
| CA2800405C (en) | Antidepressant, neuroprotectant, amyloid .beta. deposition inhibitor or age retardant containing heterocyclic compound having specific structure | |
| HRP20160334T1 (hr) | Pirano [3, 2 - d][1, 3]tiazol kao inhibitori glikozidaze | |
| GB2571950A8 (en) | New polymorph and new path to synthesize tafamidis | |
| JP2010531345A5 (OSRAM) | ||
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| JP2019503362A5 (OSRAM) | ||
| JP2016172757A (ja) | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 | |
| JP2016509047A5 (OSRAM) | ||
| HRP20230628T1 (hr) | Primjena i doziranje diaminofenotiazina | |
| JP2012532125A5 (OSRAM) | ||
| US8765790B2 (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
| RU2011152516A (ru) | Производные 2-карбоксамид-7-пиперазинил-бензофурана 774 | |
| JP6621815B2 (ja) | Ｏ−アルキル−ベンジリデングアニジン誘導体、及びミスフォールドタンパク質の蓄積と関連する障害の処置のための治療的使用 | |
| CA3182424A1 (en) | Hydroxynorketamine analogues, compositions comprising same and methods of use thereof | |
| JP6073913B2 (ja) | Ｈｓｐ調節活性を有する１，４−ジヒドピリジン誘導体 | |
| JP2014520785A5 (OSRAM) |